CARB-X
Day Zero Diagnostics Secures Additional $8.2M From CARB-X
The funding will support product development for Day Zero's whole-genome sequencing and machine learning-based diagnostic.
CARB-X Awards SpeeDx up to $3.7 Million for CT/NG Test on QuantumDx Q-POC
SpeeDx will develop a rapid, portable test for chlamydia and gonorrhea that can determine the latter's antimicrobial susceptibility, as well.
CARB-X Awards GenomeKey Up to $9.5M to Develop Rapid Diagnostic Test for Sepsis
GenomeKey's technology combines methods to separate bacterial and human DNA, next-generation sequencing, and machine learning.
Baebies Awarded up to $11.6M in CARB-X Funding for Neonatal Sepsis Test
The rapid, point-of-care test is being developed to run on the Durham, North Carolina-based company's Finder digital microfluidics instrument.
CARB-X Commits up to $13.8M to Novel Microdevices for Point-of-Care STI Test
Novel Microdevices is developing a portable, sample-to-answer instrument that is designed to perform molecular testing on untreated patient samples.